Resource Summary Report

Generated by NIF on May 11, 2025

Heptares Therapeutics

RRID:SCR_000499

Type: Tool

Proper Citation

Heptares Therapeutics (RRID:SCR_000499)

Resource Information

URL: http://www.heptares.com/

Proper Citation: Heptares Therapeutics (RRID:SCR_000499)

Description: A drug discovery company focused on small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. They are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilization, structure determination, and fragment-based discovery. Their partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Their objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, ADHD and chronic migraine.

Synonyms: Heptares Therapeutics Limited, Heptares Therapeutics Ltd, Heptares

Resource Type: commercial organization

Keywords: g-protein coupled receptor, small molecule, drug, biotechnology, medicine, antibody, drug discovery

Related Condition: Alzheimer's disease, Schizophrenia, Diabetes, Attention deficit-hyperactivity disorder, Chronic migraine

Funding:

Resource Name: Heptares Therapeutics

Resource ID: SCR_000499

Alternate IDs: nlx_158498, grid.450873.d, ISNI: 0000 0004 0456 4700

Alternate URLs: https://ror.org/051fk5x88

Record Creation Time: 20220129T080201+0000

Record Last Update: 20250420T013952+0000

Ratings and Alerts

No rating or validation information has been found for Heptares Therapeutics.

No alerts have been found for Heptares Therapeutics.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We have not found any literature mentions for this resource.